Therapeutic effects of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia.
Drug combinations of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin were active in the therapy of mice with intracerebral implants of the L1210 tumor. In in vivo mouse brain adenosine deaminase studies, inhibition of 9-beta-D-arabinofuranosyladenine deamination for periods of up to 24 hr was found after a single i.p. dose of 0.002 mmole/kg.
D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001381:Azepines / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D003853:Deoxyribonucleosides / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D009700:Nucleoside Deaminases / Q000037:antagonists & inhibitors*; D014740:Vidarabine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
D058892:Adenosine Deaminase Inhibitors; D000970:Antineoplastic Agents; D001381:Azepines; D003853:Deoxyribonucleosides; D009700:Nucleoside Deaminases; D014740:Vidarabine